[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Priovant Therapeutics, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":71},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100591307","phase-2-a-phase-2-study-of-the-safety-and-efficacy-of-brepocitinib-in-adults-with-cutaneous-sarcoidosis-beacon-100591307",false,"NCT06978725","A Phase 2\u002F3 Study of Brepocitinib in Adults With Cutaneous Sarcoidosis","A Phase 2\u002F3 Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults With Cutaneous Sarcoidosis","BEACON","Inclusion Criteria:\n\n1. Adults subjects\n2. Cutaneous sarcoidosis with characteristic skin biopsy histology\n3. A CSAMI activity score ≥ 10\n4. Weight \\> 40 kg to \\\u003C 130 kg, and with a body mass index (BMI) ≤ 45 kg\u002Fm2.\n\nExclusion Criteria\n\n1. History of cancer, with the exception of the following cancers with documentation of complete resection and no evidence of recurrence for ≥ 1 year: basal cell carcinoma, squamous cell carcinoma, or carcinoma in situ of the uterine cervix.\n2. High risk of thrombosis or cardiovascular disease\n3. High risk of herpes zoster\n4. Active or recent infection","ALL","18 Years",{"count":20,"type":21},168,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE2","PHASE3","This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with cutaneous sarcoidosis.",[28],"Cutaneous Sarcoidosis",[30,31,32],"sarcoidosis","cutaneous sarcoidosis","brepocitinib","RECRUITING","2026-08-19",{"date":36,"type":37},"2026-08-21","ACTUAL",{"date":39,"type":37},"2025-04-09",{"date":41,"type":21},"2029-12-31",{"name":43,"class":44},"Priovant Therapeutics, Inc.","INDUSTRY",4,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},"100633893","phase-2-a-phase-23-study-of-brepocitinib-in-adults-with-lichen-planopilaris-100633893","NCT07532603","A Phase 2\u002F3 Study of Brepocitinib in Adults With Lichen Planopilaris","A Phase 2\u002F3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults With Lichen Planopilaris","ALPINE","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Scalp biopsy consistent with LPP\n3. Active and symptomatic LPP at screening and baseline-\n4. Weight \\> 40 kg to \\\u003C 130 kg with BMI ≤ 45 kg\u002Fm2\n\nExclusion Criteria:\n\n1. History of: Lymphoproliferative disorder; Active malignancy; History of cancer within 5 years prior to baseline (exceptions for basal cell carcinoma, squamous cell carcinoma, ductal carcinoma in situ of the breast, carcinoma in situ of the uterine cervix, or thyroid cancer).\n2. High risk of thrombosis or cardiovascular disease\n3. High risk of herpes zoster\n4. Active or recent infection",{"count":55,"type":21},342,[24,25],"This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with lichen planopilaris",[59],"Lichen Planopilaris",[32,61],"lichen planopilaris","2026-07-06",{"date":64,"type":37},"2026-07-08",{"date":66,"type":37},"2026-03-19",{"date":68,"type":21},"2029-07-31",{"name":43,"class":44},61,""]